Details for Patent: 9,925,212
✉ Email this page to a colleague
Which drugs does patent 9,925,212 protect, and when does it expire?
Patent 9,925,212 protects VELTASSA and is included in one NDA.
This patent has eighteen patent family members in nine countries.
Summary for Patent: 9,925,212
| Title: | Potassium-binding agents for treating hypertension and hyperkalemia |
| Abstract: | The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function. |
| Inventor(s): | Klaerner; Gerrit (Hillsborough, CA), Berman; Lance (San Francisco, CA) |
| Assignee: | Relypsa, Inc. (Redwood City, CA) |
| Application Number: | 15/287,179 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,925,212 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,925,212
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-004 | Oct 2, 2023 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERKALEMIA | ⤷ Try a Trial | ||||
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-001 | Oct 21, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERKALEMIA | ⤷ Try a Trial | ||||
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-002 | Oct 21, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERKALEMIA | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,925,212
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013329451 | ⤷ Try a Trial | |||
| Australia | 2018260862 | ⤷ Try a Trial | |||
| Australia | 2020294307 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
